Code |
Definition |
1 |
Treatment failure (i.e. virological, immunological, and /or clinical failure) |
1.1 |
Virological failure |
1.2 |
Partial virological failure |
1.3 |
Immunological failure - CD4 drop |
1.4 |
Clinical progression |
1.5 |
Resistance (based on test result) |
2 |
Abnormal fat redistribution |
3 |
Concern of cardiovascular disease |
3.1 |
Dyslipidaemia |
3.2 |
Cardiovascular disease |
4 |
Hypersensitivity reaction |
5 |
Toxicity, predominantly from abdomen/G-I tract |
5.1 |
Toxicity - GI tract |
5.2 |
Toxicity - Liver |
5.3 |
Toxicity - Pancreas |
6 |
Toxicity, predominantly from nervous system |
6.1 |
Toxicity - peripheral neuropathy |
6.2 |
Toxicity - neuropsychiatric |
6.3 |
Toxicity - headache |
7 |
Toxicity, predominantly from kidneys |
8 |
Toxicity, predominantly from endocrine system |
8.1 |
Diabetes |
9 |
Haematological toxicity (anemia, etc.) |
10 |
Hyperlactataemia/lactic acidosis |
11 |
Bone toxicity |
15 |
Social contra-indication |
16 |
Contra-indication unspecified |
16.8 |
Contra-indication expired |
16.9 |
Contra-indication - other |
17 |
MTCT regimen completed |
70 |
Pregnancy - toxicity concerns (during pregnancy) |
75 |
Pregnancy - switch to a more appropriate regimen for PMTCT |
88 |
Death |
90 |
Side effect - any of the above not mentioned |
90.1 |
Comorbidity |
91 |
Toxicity - other (not mentioned above) |
91.1 |
Toxicity - unspecified |
92 |
More effective treatment available |
92.1 |
Simplified treatment available |
92.2 |
Treatment too complex |
92.3 |
Drug interaction |
92.31 |
Drug interaction - commencing TB/BCG treatment |
92.32 |
Drug interaction - ended TB/BCG treatment |
92.33 |
Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) |
92.4 |
Protocol change |
92.5 |
Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) |
92.6 |
End of empiric therapy |
92.9 |
Change in treatment not due to side-effects, failure, poor adherence or contra-indication |
92.91 |
Change to a generic drug |
92.92 |
Change to branded drug |
93 |
Structured Treatment Interruption (STI) |
93.1 |
Structured Treatment Interruption (STI)-at high CD4 |
94 |
Patient's wish/ decision, not specified above |
94.1 |
Non-compliance |
94.2 |
Defaulter |
95 |
Physician's decision, not specified above |
96 |
Pregnancy |
96.1 |
Pregnancy intended |
96.2 |
Pregnancy ended |
97 |
Study treatment |
97.1 |
Study treatment commenced |
97.2 |
Study treatment completed |
97.6 |
Drug not available |
98 |
Other causes, not specified above |
99 |
Unknown |